Publications

The following posters and presentations regarding OncoSec’s technology and clinical data have been presented at several scientific conferences and meetings

handoutascositc

Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12)

ASCO-SITC 2017

Download the Handout

poster2

Phase II Study of Intratumoral Plasmid Interleukin 12 (pIL-12) with Electroporation

SITC 2016

Download Poster

Download the Handout

Eurogin 2016 Presentation

Intratumoral IL-12 Therapy in HNSCC

EUROGIN 2016

Download the Poster

Helix Poster

A Novel Applicator for Endoscopic Gene Electro-Transfer

AACR Engineering and Physical Sciences in Oncology

Download the Poster

Feedback Poster

Feedback Optimized Gene Electro-Transfer for Immunotherapy

AACR Engineering and Physical Sciences in Oncology

Download the Poster

r113_9_aacr_2015

Priming response to anti-PD1/PDL1 blockade with intratumoral electroporation of plasmid IL-12 in advanced melanoma

American Association for Cancer Research Annual Meeting 2016

Download the Presentation

r113_9_aacr_2015

In vivo Intratumoral Electroporation of Gp96-Ig/Fc-OX40L Stimulates CD8+ T cell Cross Priming to Tumor-Specific Neoantigens

American Association for Cancer Research Annual Meeting 2016

Download the Poster

Intratumoral Delivery of Interleukin-12 DNA via In Vivo Electroporation Leads to Regression of Injected and Non-Injected Tumors in Merkel Cell Carcinoma

2015 European Cancer Congress

Download the Presentation 

Development of a Catheter-Based Applicator for Immuno-Oncology

First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies

Download the Poster 

Advances in Clinical Electroporation: Tissue Sensing, Feedback Control, and Catheter Technology

First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies

Download the Presentation 

Immune Correlates of Intratumoral IL-12 Electroporation

European Society for Medical Oncology 2014 Annual Meeting

Download the Poster 

Systemic Anti-Tumor Effect and Clinical Response in a Phase 2 Trial of Intratumoral Electroporation of Plasmid Interleukin-12 in Patients with Advanced Melanoma

American Society of Clinical Oncology 2014 Annual Meeting

Download the Poster 

Phase II OMS

Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)

Melanoma Bridge Meeting 2014

Download the Presentation

OncoSec’s scientists and researchers from collaborating organizations have published several scientific articles regarding intratumoral immunotherapies and electroporation DNA delivery in peer-reviewed journals.

Chen, DS. et. al. “Oncology Meets Immunology: The Cancer-Immunity Cycle.” Immunity. 2013 Jul 25; 39 (1):1–10. DOI: dx.doi.org/10.1016/j.immuni.2013.07.012.

Daud AI, Pierce, RH, et al. “Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma.” J Clin Invest. 2016 Aug 15. DOI:10.1172/JCI87324.

Daud AI, et. al. “Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma.” J Clin Oncol 26:5896-5903. DOI: 10.1200/JCO.2007.15.6794.

Herbst RS, et. al. “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.” Nature. 2014 Nov27;515(7528): 563–567. DOI: 10.1038/nature14011.

Kerkar SP, et. al. “IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.” J Clin Invest. 2011;121(12):4746–4757. DOI: 10.1172/JCI58814.

Kohrt HE, et. al. “Combination strategies to enhance antitumor ADCC.” Immunotherapy. 2012 May; 4(5): 511–527. DOI: 10.2217/imt.12.38.

Lucas ML, et. al. “IL-12 Plasmid Delivery by in Vivo Electroporation for the Successful Treatment of Established Subcutaneous B16.F10 Melanoma.” Mol Ther. 2002 Jun;5(6):668-75. DOI: 10.1006/mthe.2002.0601.

Marabelle, A. et. al. “Intratumoral Immunization: A New Paradigm for Cancer Therapy.” Clin Cancer Res 2014;20:1747-1756. DOI: 10.1158/1078-0432.CCR-13-2116.

Pardoll DM. “The blockade of immune checkpoints in cancer immunotherapy.” Nat Rev Cancer. 2012 Mar 22;12(4):252-64. DOI: 10.1038/nrc3239.

Pierce RH, et. al. “In-situ tumor vaccination: Bringing the fight to the tumor.” Human Vaccines & Immunotherapeutics. 2015; 11(8): 1901-1909. DOI: 10.1080/21645515.2015.1049779.

Sin J, et. al. “Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180–188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-c-dependent manner: application of Trp2180–188 peptides.” Cancer Immunol Immunother. 2012;61:1671–1682. DOI: 10.1007/s00262-012-1214-8.

Spranger S, et. al. “Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T-cells.” Sci Transl Med. 2013; 5, 200ra116. DOI: 10.1126/scitranslmed.3006504.

Tumeh PC, et. al. “PD-1 blockade induces responses by inhibiting adaptive immune resistance.” Nature. 2014 Nov 27;515(7528):568-71. DOI: 10.1038/nature13954.

Real Time Web Analytics